|
| Press Releases |
|
 |
|
| Tuesday, August 27, 2024 |
|
|
First Results From Lexaria's Second GLP-1 Human Pilot Study |
| more info >> |
|
| Thursday, August 22, 2024 |
|
|
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Wednesday, August 21, 2024 |
|
|
Positive Interim Blood Sugar Results From Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Monday, August 19, 2024 |
|
|
Positive Results from Lexaria's Molecular Characterization Study Monomeric form of GLP-1 drug preserved by DehydraTECH |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings from its applied research program together with the National Research Council of Canada ("NRC") that evaluated important mode of action facets of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide. more info >> |
|
| Monday, July 8, 2024 |
|
|
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards. more info >> |
|
| Wednesday, May 8, 2024 |
|
|
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study participants has already concluded. more info >> |
|
| Monday, May 6, 2024 |
|
|
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide, related to its mode of action and performance. more info >> |
|
| Tuesday, April 16, 2024 |
|
|
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party ethics review board, for human pilot study #2 (the "Study"), investigating GLP-1 drugs and DehydraTECH. more info >> |
|
| Tuesday, April 2, 2024 |
|
|
Lexaria Awarded New Patents |
| more info >> |
|
| Thursday, March 14, 2024 |
|
|
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 31, 2025 12:30 JST
|
|
|
Genetec reinforces foundation for growth, maintains resilient outlook
Aug 30, 2025 23:59 HKT/SGT
|
|
|
Integrated Development of Four Major Businesses to Drive the Financial 'Five Major Areas', GF Securities Announces its 2025 Interim Results
Aug 30, 2025 16:08 HKT/SGT
|
|
|
Global New Material International Establishes Asia-Pacific Headquarters in Hangzhou, Advancing Global Integration
Aug 30, 2025 10:54 HKT/SGT
|
|
|
Gome Retail's H1 2025 Significant Performance Improvement, Debt Resolution Breakthrough, and Accelerated Strategic Transformation
Aug 29, 2025 22:15 HKT/SGT
|
|
|
CITIC Limited reports solid H1 2025 results with higher dividend
Aug 29, 2025 20:51 HKT/SGT
|
|
|
AI-Powered Foundation, Innovation-Driven Empowerment, Legend Holdings Reports RMB699 Million in Net Profit Attributable to Parent for 2025H1
Aug 29, 2025 19:13 HKT/SGT
|
|
|
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST
|
|
|
Analogue 2025 Interim Results Net Profit Reaches HK$80.8 Million
Aug 29, 2025 17:42 HKT/SGT
|
|
|
Black Spade calls for family offices to increase their focus on digital assets and emerging industries 
Aug 29, 2025 17:32 HKT/SGT
|
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST
|
|
|
TechInnovation 2025 Returns with 3 Days of Game-Changing Innovation
Aug 29, 2025 16:00 HKT/SGT
|
|
|
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST
|
|
|
JF SmartInvest Holdings Ltd Returns to Profit in 2025 Interim Results
Aug 29, 2025 11:24 HKT/SGT
|
|
|
Fosun's Bold Innovation & Globalization Drive Valuation Upside
Aug 29, 2025 10:14 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
